Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a committed dividend through its transformation.
Overview
Is it better to pay a premium for explosive growth or hunt for value in a steady giant? This is the central question for investors choosing between Eli Lilly (NYSE:LLY) and Pfizer (NYSE:PFE).
Eli Lilly has transformed into a growth powerhouse led by its blockbuster metabolic treatments for weight loss and diabetes. Meanwhile, Pfizer is repositioning itself through strategic acquisitions to offset patent cliffs and declining pandemic-related revenue. Both companies are giants in the healthcare space, yet they offer vastly different risk and reward profiles for 2026.
Details
Eli Lilly develops and markets a wide range of medicines, but its primary focus has shifted heavily toward metabolic health. The company is currently dominated by its GLP-1 platform, which includes blockbuster treatments for diabetes and obesity, making it a standout among pharmaceutical stocks. Its reach is further affected by recent decisions from CVS Health (NYSE:CVS) to limit coverage for specific weight-loss medications on certain insurance plans.
Source
Originally published at www.fool.com.